For decades, oncology has faced a brutal wall when treating late-stage cancers: standard therapies often fail once a tumor develops resistance, leaving patients with dwindling options and grim survival timelines.
In a recent conversation on The Financial Survival Network, host Kerry Lutz sat down with Dr. Vlad Vitoc, CEO of MAIA Biotechnology (NYSE American: MAIA), to discuss a novel therapy that doesn’t just slow down cancer—it hijacks the very mechanism cancer cells use to become immortal.
The Science: Hijacking Telomerase
To understand MAIA’s lead drug candidate, ateganosine (THIO), you have to look at telomeres—the protective caps at the ends of our chromosomes.
In healthy cells, telomeres shorten every time a cell divides until the cell eventually ages and dies.
In roughly 85% of human cancers (and up to 100% in certain types like small cell lung cancer), an enzyme called telomerase is reactivated. It endlessly rebuilds those telomeres, granting cancer cells “replicative immortality.”
Previous drug attempts tried to block telomerase. Ateganosine does the exact opposite: it uses telomerase.
Because ateganosine is a modified DNA building block, telomerase actively picks it up and inserts it directly into the cancer cell’s telomeres. This creates a faulty, unstable structure that causes the telomeres to collapse and the DNA to unwind. Within 24 to 72 hours, 70% to 90% of the cancer cells die. Because less than 1% of normal healthy cells express telomerase, collateral damage to healthy tissue remains remarkably low.
The “One-Two Punch” with Immunotherapy
The destruction of the telomeres triggers a second, equally critical mechanism. The shattered telomeric fragments form micronuclei that act as red flags for the body’s immune system. Essentially, ateganosine wakes up the immune system and trains it to recognize the tumor. When followed by a standard checkpoint inhibitor (like Keytruda, Libtayo, or Tecentriq), the combination acts as a one-two punch.
The Clinical Data & Road Ahead
The results from MAIA’s Phase 2 trials in third-line non-small cell lung cancer—patients who have already failed both chemotherapy and immunotherapy—show a massive leap over the current standard of care:
Disease Control Rate: 88% (compared to 25%–35% with standard chemotherapy).
Median Overall Survival: 17.8 months (more than triple the 5.8 months typically seen with chemotherapy).
Long-Term Survival: The longest-surviving trial patient is approaching four years post-initiation, with the last two years off therapy thanks to lasting immune memory.
Backed by FDA Fast Track designation, three Orphan Drug designations (liver, small cell lung, and brain cancers),and a Rare Pediatric Disease designation, MAIA is currently enrolling its pivotal Phase 3 trial across nine countries,with U.S. expansion slated for next year. Behind ateganosine sits a pipeline of 84 second-generation molecules—seven of which have already proven an order of magnitude more potent in preclinical testing.
***********************************
Disclaimer: PAID PROMOTION & DISCLOSURE:
This video/post is a paid advertisement. FSN discloses that it has received $17,500.00 in cash only (no securities) , retained by MAIA Biotechnology, Inc. as full compensation for the production and distribution of this promotional content featuring MAIA Biotechnology, Inc. (NYSE American: MAIA). FSN and its principals currently hold no shares or securities of MAIA Biotechnology, Inc. and do not intend to buy or sell any during this promotional campaign.
MAIA Biotechnology, Inc. (MAIA)
Not Financial Advice: This content is provided for informational and promotional purposes only and does not constitute investment advice, a recommendation, or a solicitation to buy or sell any securities. Investing in micro-cap and clinical-stage biotechnology stocks carries a high degree of risk, including the possible loss of your entire investment. Always conduct your own independent due diligence and consult a licensed financial advisor before making investment decisions.


